|
Selected
publications
Orgiana G, Pinna G, Camedda A, De Falco V, Santoro M,
Melillo RM, Elisei R, Romei C, Lai S, Carcassi C, Mariotti
S. A new germline RET mutation apparently devoid of
transforming activity serendipitously discovered in
a patient with atrophic autoimmune thyroiditis and primary
ovarian failure. J Clin Endocrinol Metab 2004;89:4810-6.
Santoro
M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. RET:
normal and abnormal functions. Endocrinology 2004 Aug
26 [Epub ahead of print]
Melillo
RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta
G, Fusco A, Carlomagno F, Picascia A, Tramontano D,
Tallini G, Santoro M. The oncogenic activity of RET
point mutants for follicular thyroid cells may account
for the occurrence of papillary thyroid carcinoma in
patients affected by familial medullary thyroid carcinoma.
Am J Pathol 2004;165:511-21.
Castellone
MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana
P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL,
Fusco A, Santoro M, Melillo RM. Functional expression
of the CXCR4 chemokine receptor is induced by RET/PTC
oncogenes and is a common event in human papillary thyroid
carcinomas. Oncogene 2004;23:5958-67.
Vitagliano
D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE,
Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo
RM, Santoro M. Regulation of p27Kip1 protein levels
contributes to mitogenic effects of the RET/PTC kinase
in thyroid carcinoma cells. Cancer Res 2004;64:3823-9.
|